Estimating the impact of influenza vaccination of low-risk 50–64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK
Open Access
- 2 January 2023
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (1) , 2187592
Abstract
Co-circulation of influenza and SARS-CoV-2 has the potential to place considerable strain on health-care services. We estimate the cost-effectiveness and health-care resource utilization impacts of influenza vaccination of low-risk 50–64-y-olds in the United Kingdom (UK) against a background SARS-CoV-2 circulation. A dynamic susceptible-exposed-infected-recovered model was used to simulate influenza transmission, with varying rates of vaccine coverage in the low-risk 50–64 y age-group. Four scenarios were evaluated: no vaccination (baseline), 40%, 50%, and 60% coverage. For the 50% and 60% coverage, this rate was also applied to high-risk 50–64-y-olds, whereas 48.6% was used for the baseline and 40% coverage scenarios. Cost-effectiveness was estimated in terms of humanistic outcomes and incremental cost-effectiveness ratio (ICER), with discounting applied at 3%. Overall, influenza vaccination of 50–64-y-olds resulted in reductions in GP visits, hospitalizations, and deaths, with a reduction in influenza-related mortality of 34%, 41%, and 52% for 40%, 50%, and 60% coverage, respectively. All four scenarios resulted in acute and intensive care unit (ICU) bed occupancy levels above available capacity, although vaccination of low-risk 50–64-y-olds resulted in a 35–54% and 16–25% decrease in excess acute and ICU bed requirements, respectively. Vaccination of this group against influenza was highly cost-effective from the payer perspective, with ICERs of £2,200–£2,343/quality-adjusted life year across the coverage rates evaluated. In conclusion, in the UK, vaccination of low-risk 50–64-y-olds against influenza is cost-effective and can aid in alleviating bed shortages in a situation where influenza nd SARS-CoV-2 are co-circulating.Keywords
Funding Information
- funded by CSL Seqirus Inc
This publication has 20 references indexed in Scilit:
- Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strainsProceedings of the National Academy of Sciences, 2017
- A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccinePLOS Pathogens, 2017
- Direct and indirect effects of influenza vaccinationBMC Infectious Diseases, 2017
- Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesThe Lancet Infectious Diseases, 2016
- Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness studyBMC Medicine, 2015
- Health and economic impact of the seasonal influenza vaccination programme in EnglandVaccine, 2012
- The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based StudyPLOS ONE, 2011
- Vaccinating healthcare workers against influenza to protect the vulnerable—Is it a good use of healthcare resources?A systematic review of the evidence and an economic evaluationVaccine, 2006
- The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of ageVaccine, 2006
- Variations in population health status: results from a United Kingdom national questionnaire surveyBMJ, 1998